78 -4 (32/2) 2020 — Rizaeva M.Zh. — EFFICIENCY AND SAFETY OF ELECTRIC CARDIOVERSION IN PERSISTENT FORM OF ATRIAL FIBRILLATION

EFFICIENCY AND SAFETY OF ELECTRIC CARDIOVERSION IN PERSISTENT FORM OF ATRIAL FIBRILLATION

Rizaeva M.Zh. -Bukhara State Medical Institute, Bukhara branch of RCEMC

Resume

This article discusses strategies for managing a patient with atrial fibrillation (AF): heart rate (HR) or heart rate control. Based on our own data on the performance of cardioversion in the cardiotherapeutic resuscitation department of the RSCEMP of the Bukhara branch, an algorithm for choosing a management strategy in a particular patient is presented, the preparation and method of performing electrical cardioversion are described. To ensure the safety of the restoration of sinus rhythm, an analysis of the results of electrical impulse therapy (EIT) and complications when using various anticoagulants is given. The analysis draws conclusions about the preference of the heart rate control strategy in patients with AF and about the safety and efficacy of electrical cardioversion against the background of adequate antithrombotic therapy.

Key words: electrical cardioversion, atrial fibrillation, antithrombotic therapy, heart rate.

First page

322

Last page

325

For citation: Rizaeva M.Zh. Efficiency and safety of electric cardioversion in persistent form of atrial fibrillation//New Day in Medicine 4(32)2020 322-325

List of References

1. RSC, RSSA, RACVS guidelines for the electrophysiological studies, catheter ablation and implantable use of antiarrhythmic devices. Available at: http://www.vnoa.ru/literature/ Recomend2013.pdf. Accessed by 1 5/08/2014. Russian (Клини­ческие рекомендации РКО, ВНОА И АССХ по проведению электрофизиологических исследований, катетерной абляции и приме^е^ию имплантируемых ашиаритмических устройств. Доступно ^а: http://www.vnoa.ru/literature/Recomend2013.pdf. Проверено 1 5.08.201 4).
2. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study, Circulation 2004; 1 10:1 042-6.
3. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/ Paisley study. Heart 2001; 86: 516-21.
4. Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, Eur Heart J 2006; 27: 949-53.
5. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1 534-9.
6. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007; 28: 2803­17.
7. Knecht S, Oelschlager C, Duning T, et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008; 29: 21 25-32.
8. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010; 31: 967-75.
9. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20­year follow-up of the Renfrew/ Paisley study. Am J Med 2002; 1 13: 35964.
10. Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1 019-26.
11. Thrall G, Lane D, Carroll D, Lip GY Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006; 1 19: 448 e1-e19.
12. Roy D., Talajic M., Nattel S. et al. Rhythm control versus rate control for atrial fibrillation and heart failure // N. Engl. J. Med.- 2008. – Vol. 358. – P. 2667-2677.
13. Hsu L.F., Jais P., Sanders P. et al. Catheter ablation for atrial fibrillation in congestive heart failure // N. Engl. J. Med. – 2004. – Vol. 351. – P. 2373-2383.
14. Khan M.N., Jais P., Cummings J. et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure // N. Engl. J. Med. – 2008. – Vol. 359. – P. 1778-1785.
15. Berge E. et al. Outcomes after rhythm versus rate control in patients with atrial fibrillation: the international prospective GARFIELD registry // Eur. Heart J. – 2013. – Vol. 34, suppl. 1. – P. 551.
16. Функциональное состояние больных с фибрилляцией пред­сердий. Данные исследования AFFIRM [Электронный ре­сурс]. – URL: http://www.medmir.com/content/view/705Z9 (дата обрангения 15.02.2015).
17. Ezekowitz M.D., Cappato R. Klein A.L., Camm A.J. et al. Rationale and design of the eXplore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in patients with nonvalvular atrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion // Am. Heart J. – 2014. – Vol. 167(5). – P. 646-652.
18. Татарский Б.А., Нефедова Н.В. Электрическая наружная кардиоверсия при лечении пароксизмальной фибрилляции предсердий //Вестник аритмологии. – 2000. – № 19. -С. 95-99.
19. Попов С.В., Аубакирова Г.А., Антонченко И.В. и др. Эффек­тивность аитиаритмическою препарата III класса нибентана у больных с фибрилляцией предсердий // Вестник арит- мологии. – 2003. – № 31. – С. 10-14.
20. Востриков В.А. Эффективность и безопасность электроим- пульсдюй терапии фибрилляции предсердий // Методы не- линейного анализа в кардиологии и ожологии / под ред. Р.З. Назирова. – М.: Универсччтет, 2010. – С. 73-79.
21. Ашитромботическая терапия при мерцательной аритмии: учебно-методическое пособие / под ред. проф. Б.А. Сидо- режо. – М., 2010. – С. 46-47.